PMDA's Summary of their Assessment
Review of Seven Renal Safety Biomarkers
Submitted in August 2009 by the Critical
Path Institute's Predictive Safety Testing
Consortium (PSTC).

Unofficial English translation from the official Japanese document.
Translated for PSTC by Three S Japan Co., Ltd., and reviewed and
confirmed by Banyu Pharmaceutical Co., Ltd. (a subsidiary of Merck &
Co., Inc., U.S.A.), and Novartis Pharma K.K.
Record for pharmacogenomics/biomarker consultation

Concerning the following pharmacogenomics/biomarker consultation requested, the documents submitted by the applicant of consultation (“applicant” in the following) and the brief summary of assessment by Pharmaceuticals and Medical Devices Agency (“PMDA” in the following) are as follows.

Description

Date and No. of receipt: August 12, 2009, #P-BM1
Objective biomarkers for consultation: Urinary kidney injury molecule (Kim-1), urinary clusterin, urinary albumin, urinary trefoil factor-3 (TFF3), urinary cystatin C, urinary β2-microglobulin, urinary total protein
Category of consultation: Pharmacogenomics/biomarker consultation
Consultation applicant: Critical Path Institute’s Predictive Safety Testing Consortium (PSTC)
Department (field) in charge: Omics Project Team

1. Brief summary of the submitted documents

(1) Background

Early diagnosis of drug-induced acute kidney injury is important for early decision of discontinuation of causative drugs or therapeutic strategy for the injury, etc. At present, serum creatinine (“sCr” in the following) and blood urea nitrogen (“BUN” in the following), etc. are used as clinical and non-clinical biomarkers (“BM” in the following) for kidney injury, but they are not sufficient in specificity and sensitivity.

Therefore, to investigate novel BMs superior in specificity and sensitivity to these existent BMs for acute kidney injury, the applicant examined 23 urinary BMs in total (albumin, β2-microglobulin, calbindin d28, clusterin, cystatin C, EGF, GST α, GST μ, kidney injury molecule [“Kim-1” in the following], lipocalin2 [NGAL], macrophage migration inhibitory factor, monokine induced by interferon γ, interferon γ induced 10Kda protein, NAG, osteoactivin, osteopontin, podocin, RPA1, Timp1, trefoil factor-3 [“TFF3” in the following], total protein, uromodulin [Tamm-Horsfall] and VEGF). As the result, the applicant considered that usefulness as BM for drug-induced acute kidney injury has been proved and qualification for specific context of usage has been confirmed for 7 novel BMs (urinary Kim-1, urinary clusterin, urinary albumin, urinary TFF3, urinary cystatin C, urinary β2-microglobulin and urinary total protein; these means urinary BMs in the following unless noted) at present, and requested this consultation to confirm the appropriateness. The applicant explained that similar documents had been already submitted to FDA and EMEA (EMA at present) for qualification of the 7 novel BMs in 2008, and that these were judged to be qualified as BMs to detect acute kidney injury in rats in non-clinical studies.

(2) Consultation items

The following 3 items were presented by the applicant as the objectives for submission of documents for qualification of BMs in the consultation:

1) To report results obtained by the applicant concerning several BMs for drug-induced acute kidney injury.

2) To seek agreement of PMDA for the idea that the non-clinical study data concerning the 7 novel BMs submitted this time support the opinion of the applicant for qualification of each novel BM on the basis of clinical study data in published literatures as well.

3) To explain the strategy for the additional studies and qualification proposed to gain broader
acceptance and better understanding for usage of the 7 novel BMs and other promising BMs for drug-induced kidney injury in NDA, and to seek agreement of PMDA for that matter.

(3) Brief summary of the studies performed by the applicant

In the present consultation, the applicant considered that the 7 novel BMs (Kim-1, clusterin, albumin, TFF3, cystatin C, β2-microglobulin and total protein) were confirmed for their usefulness as BMs for drug-induced acute kidney injury, and the documents in Attachment 2 were submitted by the applicant. The content included the results of short term (3 weeks) rat toxicity studies using existent chemicals known to cause acute renal injury, and the studies were performed in 3 parties including Merck (20 studies), Novartis Pharma (10 studies) and FDA (4 studies). In addition, assessment results of published literatures concerning clinical studies were also submitted.

Two different strains of rats were used in the rat toxicity studies. Han Wistar rats were used in the studies in Novartis Pharma, and Sprague-Dawley rats were used in the studies in Merck and FDA. Brief summary of the rat toxicity studies performed is shown in Table 1.

<table>
<thead>
<tr>
<th>Testing facility</th>
<th>Merck</th>
<th>Novartis Pharma</th>
<th>FDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strain of rats</td>
<td>Sprague-Dawley</td>
<td>Han Wistar</td>
<td>Sprague-Dawley</td>
</tr>
<tr>
<td>Sex</td>
<td>Male(^a)</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td>No. of animals per group</td>
<td>4-6</td>
<td>6</td>
<td>3-6</td>
</tr>
<tr>
<td>No. of nephrotoxicants(^b)</td>
<td>11</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>No. of non-nephrotoxicants(^c)</td>
<td>9</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>BMs measured</td>
<td>Kim-1, albumin, TFF3, sCr, BUN</td>
<td>Kim-1, clusterin, cystatin C, β2-microglobulin, total protein, sCr, BUN</td>
<td>Kim-1, sCr, BUN</td>
</tr>
</tbody>
</table>

\(^a\): Only 1 study using carbapenem included females.
\(^b\): gentamicin, vancomycin, doxorubicin, furosemide, lithium carbonate, cisplatin, puromycin, tacrolimus, carbapenem, cyclosporine, thioacetamide, hexachlorobutadiene, allopurinol, phenylanthranilic acid, D-serine, propyleneimine, mercuric chloride, sodium dichromate
\(^c\): α-naphthyl-isothiocyanate, methapyrilene, isoproterenol, furane, genipin, cerivastatin, tetrachloromethane, trichlorobromomethane, water, 2% sodium chloride aqueous solution, 4% sucrose aqueous solution

Following treatment with nephrotoxicants and non-nephrotoxicants, histopathology data, hematology and clinical chemistry data and data of 7 novel BMs were collected, and accumulated into a common database. ROC (Receiver Operating Characteristic) analysis was performed to compare utility of these 7 novel BMs with that of sCr and BUN, the present standard BMs for kidney injury. When a change of BM is observed without a change in histopathology, it is difficult to judge exactly whether it is a change of BM preceding histopathological change or a false positive change. Therefore, in the ROC analysis, an exclusion analysis in which data of nephrotoxicant dose groups without histopathological changes are excluded from analysis was performed, and the results were presented as the main results. In addition, separately, an inclusion analysis with all test samples was also performed, in which above mentioned tested animal data were included. Furthermore, measured values of BMs for kidney injury were normalized with urinary creatinine ("UCr" in the following) value to minimize effects of experimental artifacts (leakage from water bottles, water consumption behavior due to pharmacological or toxicological effects of test article and effects on urine volume, etc.).

Major results of the ROC analysis are shown in Figure 1 and Table 2 (renal tubular injury), and Figure 2 and Table 3 (glomerular injury).
1) Renal tubular injury

Table 2: Results of ROC analysis (exclusion) in each testing facility

<table>
<thead>
<tr>
<th>Testing facility</th>
<th>BM</th>
<th>AUC$^a$</th>
<th>Threshold$^b$</th>
<th>Relative sensitivity$^b$</th>
<th>No. of test animals (control group$^c$/disease group$^d$)</th>
<th>$p$ value$^e$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck</td>
<td>Kim-1</td>
<td>0.99 (0.00)</td>
<td>1.88</td>
<td>99</td>
<td>46/77</td>
<td>0.00001</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td>0.90 (0.01)</td>
<td>2.23</td>
<td>71</td>
<td>246/224</td>
<td>9.99E-10</td>
</tr>
<tr>
<td></td>
<td>TFF3 (UCr)</td>
<td>0.90 (0.02)</td>
<td>2.01</td>
<td>78</td>
<td>105/134</td>
<td>0.70557</td>
</tr>
<tr>
<td></td>
<td>TFF3 (excreted amount)</td>
<td>0.92 (0.02)</td>
<td>2.15</td>
<td>77</td>
<td>106/111</td>
<td>0.27375</td>
</tr>
<tr>
<td></td>
<td>TFF3 (concentration)</td>
<td>0.93 (0.02)</td>
<td>2.47</td>
<td>87</td>
<td>117/135</td>
<td>0.07381</td>
</tr>
<tr>
<td></td>
<td>sCr</td>
<td>0.77 (0.02)</td>
<td>1.22</td>
<td>48</td>
<td>246/224</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUN</td>
<td>0.82 (0.02)</td>
<td>1.26</td>
<td>61</td>
<td>246/224</td>
<td>-</td>
</tr>
<tr>
<td>Novartis Pharma</td>
<td>Kim-1</td>
<td>0.91 (0.02)</td>
<td>1.87</td>
<td>79</td>
<td>283/132</td>
<td>3.02E-07</td>
</tr>
<tr>
<td></td>
<td>Clusterin</td>
<td>0.88 (0.02)</td>
<td>1.85</td>
<td>70</td>
<td>289/132</td>
<td>1.16E-04</td>
</tr>
<tr>
<td></td>
<td>sCr</td>
<td>0.73 (0.03)</td>
<td>1.15</td>
<td>40</td>
<td>289/132</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUN</td>
<td>0.79 (0.03)</td>
<td>1.20</td>
<td>51</td>
<td>289/132</td>
<td>-</td>
</tr>
<tr>
<td>FDA</td>
<td>Kim-1 (not normalized)</td>
<td>0.77 (0.04)</td>
<td>1.39</td>
<td>64</td>
<td>28/131</td>
<td>3.62E-01</td>
</tr>
<tr>
<td></td>
<td>Kim-1</td>
<td>0.84 (0.03)</td>
<td>1.77</td>
<td>68</td>
<td>28/129</td>
<td>9.53E-03</td>
</tr>
<tr>
<td></td>
<td>sCr</td>
<td>0.72 (0.05)</td>
<td>1.42</td>
<td>34</td>
<td>28/134</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>BUN</td>
<td>0.76 (0.04)</td>
<td>1.22</td>
<td>62</td>
<td>28/133</td>
<td>-</td>
</tr>
</tbody>
</table>

$^a$: Values in parenthesis are standard errors, $^b$: Values corresponding to 95-97% of specificity
$^c$: Animals without kidney-specific lesions/histopathological changes
$^d$: Animals with kidney-specific lesions/histopathological changes
$^e$: $p$<0.05 (DeLong test: AUC of each novel BM vs AUC of sCr) is shown with underline.

Figure 1: Assessment of renal tubular injury (degeneration, necrosis, apoptosis and cell sloughing) by Novartis Pharma
Determination of Kim-1 was performed in 18 studies in total including those performed by Merck (n=4), Novartis Pharma (n=10) and FDA (n=4), and the results were evaluated using the same analytical methods. As indicated in Table 2 and Figure 1, Kim-1 showed the highest values both in AUC and sensitivity from results of analysis performed in any of the facilities. The diagnostic threshold of Kim-1 to specificity 97%, 95% and 96% (in order of Merck, Novartis Pharma and FDA) was 1.88, 1.87 and 1.77, respectively, indicating consistent results obtained from independent assessment for detection performance with Kim-1 in multiple testing facilities. In addition, from the results of ROC analysis for individual histopathological findings of degeneration, necrosis, dilatation and regeneration performed by Merck in parallel with the above mentioned ROC analysis, Kim-1 was considered to outperform sCr and BUN as well as other novel BMs (albumin, TFF3), regardless of type of renal tubular injury.

Furthermore, from the results of ROC analysis performed by Merck and Novartis Pharma, both albumin and clusterin were shown to significantly outperform sCr and BUN in detection of drug-induced acute renal tubular injury. Although TFF3 did not show significant difference from sCr and BUN in detection of renal tubular injury, it was considered that TFF3 was indicated to have usefulness superior to sCr and BUN in detection of drug-induced acute renal tubular regeneration and dilatation, from the results of ROC analysis for individual histopathological findings performed by Merck.

2) For glomerular injury

Table 3: Results of ROC analysis (exclusion) in Novartis Pharma

<table>
<thead>
<tr>
<th>BM</th>
<th>AUCb</th>
<th>Thresholdb</th>
<th>Relative sensitivityb</th>
<th>No. of test animals (control groupc/disease groupd)</th>
<th>p valuee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystatin C</td>
<td>0.91 (0.03)</td>
<td>3.11</td>
<td>65</td>
<td>291/40</td>
<td>1.47E-06</td>
</tr>
<tr>
<td>β2-microglobulin</td>
<td>0.89 (0.03)</td>
<td>3.59</td>
<td>73</td>
<td>291/40</td>
<td>1.72E-05</td>
</tr>
<tr>
<td>Total protein</td>
<td>0.86 (0.04)</td>
<td>1.90</td>
<td>78</td>
<td>291/40</td>
<td>1.12E-05</td>
</tr>
<tr>
<td>sCr</td>
<td>0.53 (0.05)</td>
<td>0.91</td>
<td>30</td>
<td>291/40</td>
<td>-</td>
</tr>
<tr>
<td>BUN</td>
<td>0.80 (0.04)</td>
<td>1.29</td>
<td>48</td>
<td>291/40</td>
<td>-</td>
</tr>
</tbody>
</table>

a: Values in parenthesis are standard errors, b Values corresponding to 99% of specificity
c: Animals without kidney-specific lesions/histopathological changes
d: Animals with kidney-specific lesions/histopathological changes
e: p<0.05 (DeLong test: AUC of each novel BM vs AUC of sCr) is shown with underline.
Cystatin C, β2-microglobulin and total protein were indicated to significantly outperform sCr and to can outperform BUN in detection of glomerular injury and following urinary tubular reabsorption disorder.

Furthermore, relative sensitivity (value corresponding to 99% specificity) and relative specificity (specificity corresponding to 85% sensitivity) calculated on the basis of the results of ROC analysis were 65% and 92% in cystatin C, 73% and 89% in β2-microglobulin, 78% and 49% in total protein, 30% and 0% in sCr and 48% and 49% in BUN, respectively, indicating that cystatin C and β2-microglobulin are with high sensitivity in detection of mild glomerular injury and following renal tubular reabsorption impairment and that total protein is with high specificity in detection of glomerular injury and following renal tubular reabsorption impairment.

(4) Assessment of clinical study results in published literatures

Results of assessment of published literatures in which clinical study results were reported supporting clinical use of Kim-1, albumin, cystatin C, β2-microglobulin and total protein were presented for each BM, and a discussion that all of the 5 novel BMs represent kidney injury BMs with high-sensitivity in humans was shown (Attachment 2, Document No. 5). In addition, an claim of the applicant was shown, in which the applicant insisted that use of BMs in early clinical studies is appropriate for those among the novel 5 BMs which demonstrated changes in animal studies with sufficient sensitivity after treatment with specific test drugs, based on the present assessment results as well as the results of non-clinical study outlined in the former section.

(5) Future plan of the applicant

1) Experimental strategy

As a plan for next step after the present consultation, the following examination items were presented by the applicant.

(i) Conduct of additional assessment for 7 novel BMs as well as sCr and BUN using remnant samples from the rat toxicity studies performed before this consultation.

(ii) Assessment of another BM candidates (NAG, GST-α, GST-μ, osteopontin, lipocalin-2, uromodulin, RPA-1, osteoactivin and calbindin d28) for performance on detection of kidney injury
using the remnant samples shown in (i).

(iii) Further assessment for specificity of the 7 novel BMs in detection of kidney injury using samples obtained from the studies with non-nephrotoxicants.

(iv) Conduct of a few additional studies in rats and humans to investigate additional claims concerning usage of the 7 novel BMs.

2) Potential gaps

The following items were presented by the applicant as potential gaps to be examined in next qualification concerning the 7 novel BMs:

(i) As the present consultation is focused on acute toxicity studies, it is also necessary to perform assessment for changes in novel BMs against chronic kidney injury in studies in which dose levels of nephrotoxicants, treatment period and observation period are appropriately selected.

(ii) Changes in the novel BMs up to appearance of renal lesions and up to disappearance or recovery of the lesions are also necessary to be assessed.

(iii) Assessment of the novel BMs should be performed also in animal species other than rats, to confirm biological significance of changes of the novel BMs.

(iv) When a novel BM is used for safety monitoring in early clinical studies, historical control (normal) values in the targeted clinical population should be established.

(v) For BMs other than the 7 novel BMs in which usefulness in detection of drug-induced acute kidney injury has been non-clinically confirmed but no clinical experience has been obtained, assessment with small scale clinical studies will be performed to show validity for usage in clinical studies.

2. Brief summary of assessment

Brief summary of opinion of the applicant and assessment by PMDA concerning qualification of each novel BM is as follows:

(1) Consultation item 2. For the opinion of the applicant concerning qualification of each novel BM

The applicant explained that they considered to qualify the 7 novel BMs for following context of use 1-3 based on the submitted documents (Table 4).

1) In rat toxicity studies, 6 among 7 of the novel BMs excluding TFF3 (Kim-1, clusterin, albumin, cystatin C, β2-microglobulin and total protein) can outperform and add information to BUN and sCr as early diagnostic BMs for drug-induced acute renal tubular alterations or drug-induced acute glomerular alterations/damage. In addition, although TFF3 could not outperform BUN and sCr, it provides additional information as early diagnostic BMs for drug-induced acute renal tubular alterations to those obtained from BUN and sCr.

2) The applicant considers that these 7 novel BMs are qualified for regulatory decision making as BMs that may be used by sponsors on a voluntary basis to demonstrate that drug-induced acute renal tubular alteration or drug-induced acute glomerular alterations/damage are monitorable in GLP rat studies which are used to support safe conduct of clinical trials.

3) The applicant considers that 5 novel BMs (Kim-1, albumin, cystatin C, β2-microglobulin and total protein) out of 7 novel BMs excluding clusterin and TFF3 are qualified for regulatory decision making as BMs monitoring kidney safety to support further testing of drugs in clinical development (for example, phase I and phase II clinical trials) when animal toxicology findings generate a concern for renal tubular alterations or glomerular alterations/damage with associated tubular impairment and when such animal studies demonstrate early detection of reversible renal injury.

Data on novel BMs submitted this time could be used for safety assessment made by PMDA in reviewing protocols for early clinical study.
Table 4: Claims of the applicant for context of usage of the novel BMs

<table>
<thead>
<tr>
<th>BM</th>
<th>Changes in measured values on kidney injury</th>
<th>Assertion for usage of novel BMs</th>
<th>Value for measuring in addition to BUN and/or sCr</th>
<th>Type of kidney injury to be monitored</th>
<th>Existent published data supporting claims concerning clinical usefulness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim-1</td>
<td>Increase</td>
<td>Outperform BUN and/or sCr</td>
<td>Valuable</td>
<td>Renal tubule</td>
<td>Existing</td>
</tr>
<tr>
<td>Clusterin</td>
<td>Increase</td>
<td>Outperform BUN and sCr</td>
<td>Valuable</td>
<td>Renal tubule</td>
<td>Not existing</td>
</tr>
<tr>
<td>Albumin</td>
<td>Increase</td>
<td>Outperform BUN and sCr</td>
<td>Valuable</td>
<td>Renal tubule</td>
<td>Existing</td>
</tr>
<tr>
<td>TFF3 (UCr-normalized)</td>
<td>Decrease</td>
<td>Not outperform</td>
<td>Valuable</td>
<td>Renal tubule</td>
<td>Not existing</td>
</tr>
<tr>
<td>Cystatin C</td>
<td>Increase</td>
<td>Outperform sCr</td>
<td>Valuable</td>
<td>Glomerulus</td>
<td>Existing</td>
</tr>
<tr>
<td>β2-microglobulin</td>
<td>Increase</td>
<td>Outperform sCr</td>
<td>Valuable</td>
<td>Glomerulus</td>
<td>Existing</td>
</tr>
<tr>
<td>Total protein</td>
<td>Increase</td>
<td>Outperform sCr</td>
<td>Valuable</td>
<td>Glomerulus</td>
<td>Existing</td>
</tr>
</tbody>
</table>

a: “Renal tubule” means drug-induced acute renal tubular alterations and “Glomerulus” means drug-induced acute glomerular alterations/damage with associated kidney tubular reabsorption impairment.

1) Context of usage of novel BMs presented

(i) For albumin

PMDA required explanation of the applicant whether it is appropriate that albumin is one of valid BMs for “renal tubular alterations”, similar to Kim-1, clusterin or TFF3, (or whether it is necessary that albumin is a BM with more limited context of usage), based on the results of ROC analysis (inclusion) for albumin with renal tubular dilatation and regeneration among urinary tubular alterations detected by histopathology. In that analysis, AUC and sensitivity values of albumin lower than those of sCr and BUN were observed. AUC values for renal tubular dilatation were 0.88 ± 0.05, 0.95 ± 0.03 and 0.86 ± 0.05 for albumin, sCr and BUN, respectively. Sensitivity values for renal tubular dilatation were 0.50, 0.71 and 0.63 for albumin, sCr and BUN, respectively. AUC values for renal tubular regeneration were 0.78 ± 0.05, 0.84 ± 0.05 and 0.85 ± 0.05 for albumin, sCr and BUN, respectively. Sensitivity values for renal tubular regeneration were 0.41, 0.59 and 0.55 for albumin, sCr and BUN, respectively.

The answer of the applicant was as follows:

First, each of the 7 novel BMs presented in this consultation is not intended to be replaced sCr and BUN but is supposed to be used together with sCr and BUN, and albumin is considered to have been qualified based on information available at present. Next, from data of Merck showing scores for each of 3 renal tubular changes consisting of “renal tubular degeneration or necrosis”, “renal tubular regeneration” and “renal tubular dilatation” among “urinary tubular alterations”, albumin is considered to be most useful when pathologic changes to the tubules are noted, especially degeneration or necrosis (but not exclusively) that impair reabsorption by the tubular epithelium of albumin from the lumen. Although data analysis of each change does not include statistical test against sCr and BUN in order to avoid multiplicity, those are not considered to mean that albumin is inferior to other BMs in detection of changes other than urinary tubular degeneration or necrosis. On the other hand, an overall conclusion that albumin can outperforms sCr and BUN in detection of drug-induced acute renal tubular alterations according to a statistical test (DeLong’s test) has been obtained by analysis using Maximum Composite score. Therefore, at present we consider that it is not necessary to limit the claim of use of albumin to renal tubular degeneration or necrosis.

Based on the answer from the applicant, PMDA required the applicant to explain how to differentiate only functional changes without structural or pathological changes and those with structural changes including renal tubular degeneration or necrosis when albumin elevation is
observed, after showing the ratio of urine samples from non-clinical studies with increased urinary albumin, between those with structural changes including renal tubular degeneration or necrosis and those lacking those changes. In addition, PMDA required the applicant to examine for appropriateness to use albumin in combination with other novel BMs (Kim-1, TFF3, etc.), because it has been indicated that albumin is not suitable for detection of renal tubular regeneration and dilatation when used as a BM of renal structural changes.

The answer of the applicant was as follow:

Among in total 700 cases from in total 20 studies performed by Merck, number of cases with structural changes or functional changes was counted. As the result, increased albumin exceeding the 95% of specificity threshold (exclusion analysis: 2.23-fold) was observed in 240 cases, including 158 cases with “degeneration/necrosis”, 15 cases lacking “degeneration/necrosis” but with “dilatation” or “regeneration” and 67 cases lacking “degeneration/necrosis”, “dilatation” or “regeneration”. Therefore, among the samples with increased albumin, ratio of those lacking histopathological renal changes was 28% (67/240 cases). In addition, since increased albumin was observed also in samples lacking histopathological renal changes, a possibility that increased albumin may occasionally be more sensitive than histopathological findings as well as a possibility that urinary protein may occur in cases without histopathological renal changes due to direct drug-induced inhibition of functional protein uptake by proximal tubular epithelium (a mechanism without cellular injury, for example by specific competitive inhibitor of the megalin-cubilin transporter complex) were suggested. In cases in which functional protein uptake by proximal tubular epithelium is directly inhibited by a mechanism without cellular injury, urinary protein is considered to elevate without increases in BMs released into urine with cellular injury such as Kim-1. Therefore, simultaneous determination of albumin and Kim-1 may enable distinction of cases with only functional changes without structural changes. However, the utility is not considered to have been clarified at present. For possibility to distinguish specific cases by combination of multiple specific BMs, further examination with carefully designed studies is necessary, and this is considered to be a future challenge.

PMDA agrees to the explanation of the applicant that combination of multiple specific BMs to distinguish specific cases is a future challenge, but concerning albumin, PMDA considers it is not recommended to use albumin alone, but it is desirable to use it in combination with Kim-1 and TFF3, etc. as far as possible in measurement in future because a possibility that albumin is influenced by a mechanism without cellular injury cannot be excluded.

\[2\] Highest score among 3 scores for histopathological findings including renal tubular degeneration or necrosis, renal tubular regeneration and others (renal tubular dilatation, etc.).
(ii) For TFF3

PMDA required explanation of the applicant for appropriateness of the proposed context of use of TFF3, since it is the only BM with which results did not outperform sCr and BUN based on results of DeLong’s test among the novel BMs proposed this time (Kim-1, clusterin, albumin and TFF3) (Tables 2 and 4). In addition, PMDA also required explanation of the applicant which parameter of TFF3 is considered to be appropriate, because analysis and examination have been performed using normalization of TFF3 among “UCr”, “excretion” and “concentration”.

The answer of the applicant was as follows:

There has been no evidence that TFF3, if used alone, would outperforms sCr or BUN, but to assess the contribution of TFF3, the applicant analyzed the additional information that TFF3 provides within the context of a statistical model. As the result, by addition of TFF3 to a model of sCr and BUN (a binary logistic regression model with sCr and BUN as explanatory variables for histopathological response of the kidney), the likelihood ratio statistic calculated from the model improved from 187.3 to 224.4. Therefore, TFF3 is considered to be a novel BM providing useful information for detection of acute renal damage, and it is considered to be appropriate to use TFF3 in combination with current standard BMs. On the other hand, concerning normalization of TFF3, at present it is considered to be best to normalize with UCr to guard against false-positive conclusions when decreases in TFF3 concentrations are measured as a result of diuresis in the absence of injury or perhaps as a result of a leakage from water bottles during overnight urine collection. However, for appropriateness of normalization to UCr, examination based on further experience and accumulation of data is considered to be necessary, because TFF3 is the only BM among the 7 novel BMs which decreases in response to kidney injury and sufficient experience has not been accumulated. Therefore, this time the applicant judged it appropriate to present 3 kinds of normalized data.

On the basis of the answer from the applicant, PMDA required explanation of the applicant how to differentiate decrease in TFF3 due to kidney injury and decrease due to insufficient detection ability, since TFF3 is the only BM among the 7 novel BMs evaluated this time in which decrease in urine is as the measure.

The answer of the applicant was as follows:

For analytical performance of TFF3, validation (determination of lower limit of quantification, and confirmation of lack of interference by urine, test article and known contaminants) was performed first. In addition, a positive control in which recombinant TFF3 was spiked into buffer was set for each analysis and replicate analysis was performed as an additional validation.

PMDA considers that having set a positive control in performing additional validation is valuable. However, for TFF3, since it is difficult to differentiate decrease due to kidney injury and decrease due to sensitivity for detection, setting a positive control group in each analysis in principle is considered to be desirable in the studies performed in future.

Furthermore, statistical analytical results demonstrating superiority of TFF3 to sCr and BUN were not obtained among proposed renal tubular injury BMs this time, and TFF3 is the only BM which decreases in response to kidney injury among the presently proposed 7 novel BMs, and in absence of “positive control” it is difficult to differentiate effects of kidney injury and reduction in detective ability when TFF3 is used alone. Therefore, PMDA considers it is not recommended to use TFF3 alone, as with albumin, but it is desirable to use TFF3 in combination with Kim-1 or albumin, etc. as far as possible in future examinations.

2) For normalization of measured values of the novel BMs with UCr values

In the submitted literature (Han WK et al, J. Am. Soc. Nephrol. 16: 1126-1134. 2005), it is reported that normalization of Kim-1 values with UCr has a problem due to unstable creatinine balance in acute kidney injury patients, and that there was no significant difference between values before normalization and after normalization. In addition, normalization of the novel BMs with UCr had been prescribed beforehand, while for Kim-1 and TFF3, both normalized and non-normalized data were presented. As shown in these matters, assessment was performed in
mixed 2 different methods. Moreover, assessment methods and appropriateness of the normalization was judged with empirical rule according to the obtained study results. Therefore, PMDA required explanation of the applicant for appropriateness to perform the normalization with UCr for all of the novel BMs to keep scientific integrity of analytical methods.

The answer of the applicant was as follows:

We consider that experimental artifacts (for example, possibility of changes in urinary BM levels not related to kidney injury due to leakage from water bottles in animal studies, influence on water consumption behavior due to pharmacological or toxicological effects and pharmacological effects on urine volume) can be avoided by normalization of urinary BM with UCr, and that it will enable precise assessment of changes due to treatment-related kidney injury. However, as reported by Han, et al., we recognize that normalization with UCr levels may not appropriately work during the period up to reaching to stable equilibrium between sCr and UCr excretion after acute marked changes in glomerular filtration and urinary excretion of creatinine. Therefore, on normalization with UCr, it should be carefully performed together with an assessment of changes in UCr levels, in cases in which UCr decrease before increase of sCr may occur, such as acute renal dysfunction within 24 hours after onset. In cases where the results are suspected to be anomalous, repeated urine collection and measurement seem to be necessary. Based on above matters, at present, the best assessment method is considered to be to normalized values of the 7 novel BMs including TFF3 with UCr.

PMDA considers that “it should be carefully performed together with an assessment of changes in UCr levels” in explanation by the applicant is important on correction with UCr, and that compliance with this point should be a premise in all assessment of BMs proposed in this consultation. In addition, PMDA considers that detailed evaluation results for changes in UCr levels also should be presented on examination in future.

3) For blinding of histopathological assessment

At first, the histopathological assessment performed in Merck and Novartis Pharma was not blinded. Based on the discussion in the FDA/EMEA VXDS joint meeting, a blinded histopathological assessment was performed again in Merck, Novartis Pharma and SRI International (“SRI” in the following).

Concerning the ROC analysis based on these blinded histopathological reassessment results, based on the results from SRI, Merck and Novartis Pharma, the results from Merck and Novartis Pharma showed higher AUC values in comparison to the results from SRI, in most of the 7 novel BMs. PMDA required explanation of the applicant for the reason of these matters.

The answer of the applicant was as follows:

The main reason why the results from Merck and Novartis Pharma showed higher AUC than that in the results from SRI is considered to be due to difference in criteria for assessment between each assessment facility (difference in lexicons, difference in grading systems, different thresholds between pathologists, etc.). For example, on a finding of renal tubular injury, the pathologist in SRI graded very slight and considered to be pseudo-negative. On the other hand, on the same finding, the pathologist in Merck considered it to be below the threshold of diagnosis and considered to be normal variation. However, as demonstrated in the results of ROC analysis (exclusion) in these 3 facilities shown in Table 5-1 and Table 5-2, although lower AUC was obtained in SRI assessment, relative position of each BM seems to be almost similar with minimal variation. Based on the difference in assessment criteria between each facility, the difference of analytical results observed between each facility is not considered to cause significant influence on explanation for the proposed appropriateness of context of use for the 7 novel BMs.
Table 5-1: Results of ROC analysis (exclusion) using BM values in Merck

<table>
<thead>
<tr>
<th>BM</th>
<th>AUC (Merck) a</th>
<th>AUC (SRI) b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim-1</td>
<td>1.00 (NA)</td>
<td>0.98 (0.02)</td>
</tr>
<tr>
<td>Albumin</td>
<td>0.99 (0.01)</td>
<td>0.96 (0.02)</td>
</tr>
<tr>
<td>TFF3 (UCr)</td>
<td>1.00 (0.01)</td>
<td>0.97 (0.02)</td>
</tr>
<tr>
<td>sCr</td>
<td>0.95 (0.03)</td>
<td>0.90 (0.04)</td>
</tr>
<tr>
<td>BUN</td>
<td>0.90 (0.04)</td>
<td>0.91 (0.04)</td>
</tr>
</tbody>
</table>

a: AUC obtained by ROC analysis based on blinded histopathological assessment results performed in Merck; the value in parenthesis is the standard error.

b: AUC obtained by ROC analysis based on blinded histopathological assessment results performed in SRI; the value in parenthesis is the standard error.

Table 5-2: Results of ROC analysis (exclusion) using BM values in Novartis Pharma

<table>
<thead>
<tr>
<th>BM</th>
<th>AUC (Novartis Pharma) a</th>
<th>AUC (SRI) b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim-1</td>
<td>0.95 (0.02)</td>
<td>0.82 (0.04)</td>
</tr>
<tr>
<td>Clusterin</td>
<td>0.93 (0.03)</td>
<td>0.84 (0.04)</td>
</tr>
<tr>
<td>sCr</td>
<td>0.66 (0.06)</td>
<td>0.62 (0.06)</td>
</tr>
<tr>
<td>BUN</td>
<td>0.54 (0.06)</td>
<td>0.53 (0.07)</td>
</tr>
</tbody>
</table>

a: AUC obtained by ROC analysis based on blinded histopathological assessment results performed in Novartis Pharma; the value in parenthesis is the standard error.

b: AUC obtained by ROC analysis based on blinded histopathological assessment results performed in SRI; the value in parenthesis is the standard error.

PMDA considers that clear explanation has not been presented by the applicant for the reason why different terminology and different classification of severity were used among the assessment facilities on blinded histopathological reassessment, and that strict comparison of the results between facilities is difficult. Albeit these matters, PMDA does not consider that the difference in assessment results may significantly affect on assessment of context of usage of the 7 novel BMs proposed by the applicant, because the difference between the results from Merck and Novartis Pharma and the results from SRI in AUC of ROC analysis based on histopathological reassessment was not considered to be significant, and relative position of each BM obtained by ROC analysis (exclusion) was also not significantly different. On qualification of the novel BMs performed in future, we consider that histopathological assessment should be performed under blinded condition to appropriately guaranteed reliability of the assessment results.

4) For site specificity of the novel BMs in kidney injury

PMDA required explanation of the applicant for the possibility that the values of the proposed novel BMs concerning glomerular injury (β2-microglobulin, cystatin C, total protein) may increase not only in samples in which both glomeruli and renal tubules are injured but also in samples in which only renal tubules are injured.

The answer of the applicant was as follows:

In most cases, values of the new BMs for glomerular injury increased in samples in which glomerular injury associated with renal tubular reabsorption impairment was observed, and did not increase in samples in which only renal tubules were injured. However, since values of the new BMs for glomerular injury increased in the group receiving gentamicin which is not considered to induce glomerular injury, a possibility that values of these glomerular injury BMs may increase due to factors affecting renal tubular reabsorption complex cannot be considered to be excluded.

PMDA considers that usefulness of β2-microglobulin, cystatin C and total protein as novel BMs detecting drug-induced glomerular injury with renal tubular reabsorption impairment has been suggested. However, PMDA considers that a possibility that these novel BMs values concerning glomerular injury may increase in cases without glomerular injury cannot be excluded, and that it is necessary to further examine factors affecting these BM values.
5) For quantification method of Kim-1

Since most of Kim-1 values presented in this consultation were obtained with the newly developed Luminex micro-bead method, PMDA required explanation of the applicant for reliability of quantification of Kim-1 with Luminex micro-bead method, with comparison to other quantification methods including ELISA.

The answer of the applicant was as follows:

Using a subset of the same samples from 4 studies performed by Merck, concentrations of Kim-1 were determined using Luminex micro-bead method (performed in the laboratory of J. Bonventre, Brigham & Women's Hospital) and Mesoscale Discovery chemiluminescent ELISA method (“Mesoscale method” in the following) (performed in the laboratory of Z. Erdos, Merck & Co., Inc.), and correlation coefficient ($R^2$) was calculated. As the result, the mean value of $R^2$ was about 0.8 (0.83, 0.80, 0.64, 0.78), indicating correlation between the 2 quantification methods. On the other hand, the slope of each regression line showed variation at 0.48, 0.50, 0.55 and 1.8. This variation was considered to be due to the very early stage in development of Mesoscale method at the time point of determination, and difference in the Kim-1 standard samples used in Mesoscale method from the standard samples used in Bonventre laboratory, etc. However, as assessment of Kim-1 has been performed based on fold-change relative to concurrent control values or pre-treatment values, and are not considered to depend on absolute concentrations obtained using different standard samples. Therefore, the present determination results are considered to have sufficient reliability.

PMDA accepted the above explanation of the applicant.

2) Consultation item 3. For further qualification of the novel BMs

1) For the criteria in selection and combination of BMs in further qualification of novel BMs

PMDA required explanation of the applicant for the criteria in selection and combination of BMs on use of the 7 novel BMs submitted this time for drug-induced acute kidney injury.

The answer of the applicant was as follows:

We consider that the application of single novel BM or combinations of multiple novel BMs on a particular target group depends on the intended context of use of BMs by the drug development sponsor, and that it is necessary to use each BM taking the known information about its utility, threshold and limitations into account as much as possible. Therefore, in order to investigate clinical qualification of these novel BMs, we will use as many BMs as possible in the future clinical studies, and from the results advantage and disadvantage of each BM will be understood. In addition, relative relationship between each BM will be evaluated by collecting BM values determined with same samples.

PMDA accepted the idea of the applicant.

2) For study plan to solve potential gaps and tasks in opinions concerning context of use of the novel BMs

The applicant pointed out assessment of kinetic profiles (durability) of BMs in relation to lesion development and reversal on diverse nephrotoxicants as a potential gap on qualification of novel BMs. Concerning this matter, PMDA required explanation of the applicant for the following points:

(i) For plans to conduct non-clinical and clinical studies to investigate relationship between progression or recovery of renal functional impairments and time profile of novel BM level
(ii) For detailed assessment of time profile of BM level in studies presented as a solution for potential gaps

The answer of the applicant was as follows:

(i) For non-clinical studies, multiple studies in which several nephrotoxicants (for example, gentamicin or carbapenem A) are administered to rats and reversibility of toxicity is evaluated are ongoing, and in these studies, longitudinal assessment in individual animals and sacrifice of group of animals at various time points following completion of dosing are planned. In addition, additional rat recovery studies are planned or already underway using gentamicin, adriamycin, bacitracin,
cisplatin and puromycin, for example. On the other hand, for clinical studies, the applicant is pursuing to examine the longitudinal progression and regression of BM responses in patients during and after receiving standard care treatment with cisplatin to treat head and neck cancers, and similarly in patients with cystic fibrosis receiving standard of care treatment with aminoglycoside.

(ii) Novel BMs are planned to be assessed with time (for example, values on days 3, 7 and 14) in a part of non-clinical studies described in (i). In these studies, the applicant plans to assess other BMs in addition to the novel BMs, and precise relationship between values for each BM at each time point and active histopathological process carefully. Furthermore, non-clinical studies of longer duration with continuous exposure to renal toxicants at dose levels confirmed to be well tolerated in short term studies are also under planning.

PMDA accepted the idea of the applicant.

3. Opinion of PMDA
(1) Consultation item 1. For reporting of evaluation results concerning BMs for drug-induced acute kidney injury

Use of novel BMs related to drug response in development of medicines is expected to enhance and to realize creation of medicines with higher efficacy and less adverse effects. However, use of novel BMs in development of medicines without sufficient evaluation may cause false judgment. Therefore, PMDA considers that it is an important process to confirm the qualification of novel BMs for the objective and context of usage and so on at the stage before wide use of novel BMs in development of medicines. Although the analytical results submitted by the applicant this time were limited to non-clinical data, PMDA considers that such a positive evaluation performed is meaningful, and the results obtained this time constitute useful basic data in future development of medicines. In addition, PMDA expects positive conduct of continuous non-clinical and clinical evaluations for further qualification of novel BMs in future, and considers it necessary to perform assessments for qualification again when new results are obtained.

(2) Consultation item 2. For the claim of the applicant concerning qualification of each novel BM

Based on the submitted study results and results in the published literatures for clinic for 7 novel BMs concerning detection of drug-induced acute kidney injury submitted this time, PMDA considers the opinions 1-3 concerning context of usage of the 7 novel BMs submitted by the applicant (see the section of “2. (1) Consultation item 2. For the opinion of the applicant concerning qualification of each novel BM”) are acceptable as BMs providing additional information, given that these 7 novel BMs are used for the purpose to detect drug-induced acute urinary tubular changes or acute glomerular changes/injury in rat GLP studies, and they are used in combination with existent BMs (sCr and BUN).

However, PMDA considers that sufficient qualification has not been performed for general wide use of these 7 novel BMs for detection of drug-induced acute kidney injury in early clinical studies (Phase I study, etc.), and that utility of these BMs should be individually judged on the basis of results obtained in the courses of future clinical developments of drugs or a future biomarker qualification. The use of these renal biomarkers in early clinical trials in Japan and other countries may be expected on a case-by-case basis in order to gather further data to qualify their usefulness in monitoring drug-induced renal toxicity in man.

Therefore, based on the documents submitted this time, PMDA considers it desirable to perform further positive evaluation in future for at least the following non-clinical items.

1) The results of non-clinical studies submitted this time are based on short term rat toxicity studies, and changes of BMs with time during long term treatment (changes with time and persistency) and its reversibility are not considered to have been clarified.
2) As all of the 34 studies excluding 1 study were performed only in males, evaluation for sex difference is considered to be insufficient.
3) Information for organ-specificity of the test articles (effects of the used nephro-toxicants on
organs other than the kidney and effects of non-nephro-toxicants on the kidney) and site-specificity in urinary tubules or glomerulus have not been accumulated in sufficient amount, and the effects of injuries in organs other than the kidney and in specific site of the kidney on novel BMs are not considered to have been clarified.

In addition, based on the fact that there were some examination items in which different statistical analytical results were obtained between exclusion analysis (in which data of test animals without histopathological changes are excluded from analysis) and inclusion analysis (all samples are included in analysis), PMDA considers that reliability of exclusion analysis should be continuously examined in future.

(3) Consultation item 3. For further qualifications of the novel BMs

For further qualifications of the novel BMs and other drug-induced kidney injury BM with expected usefulness, PMDA considers that the continuous non-clinical study plan presented by the applicant is useful to collect data concerning the future items indicated by PMDA in the above mentioned section (2). On the other hand, concerning clinical use of the 7 novel BMs submitted this time, though additional information may be provided by use in combination with existent BMs, PMDA considers it necessary to perform a number of further clinical studies in which extensive evaluation is performed, for wide general use as BMs for detection of drug-induced kidney injury in humans. Therefore, PMDA considers it necessary to continuously evaluate the usefulness, etc. of the 7 novel BMs in future clinical studies, including the evaluation in which the 7 novel BMs are explorative used in combination with existent BMs. PMDA expects further positive evaluation in future.

End of document

List of documents submitted

<table>
<thead>
<tr>
<th>P-BM1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document No.</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>11</td>
</tr>
</tbody>
</table>

*Unofficial translation is attached to Attachment 3.